Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995523 | 0.94 | CYP19A1 (0.52) | CYP19A1CREBBPALDH1A1CNR1LMNA | |
| SCHEMBL14522481 | 0.89 | TSHR (0.50) | ALDH1A1MAPTNR2F2CNR1LMNA | |
| SCHEMBL2984166 | 0.79 | CNR1 (0.49) | CNR1 | |
| SCHEMBL2033409 | 0.78 | CNR2 (0.60) | CYP19A1CREBBPALDH1A1CNR1LMNA | |
| SCHEMBL28840703 | 0.77 | CNR1 (0.69) | CYP19A1CREBBPALDH1A1CNR1LMNA | |
| SCHEMBL2043047 | 0.76 | CNR2 (0.68) | ALDH1A1MAPTCNR1 | |
| SCHEMBL2013170 | 0.76 | CYP19A1 (0.57) | CYP19A1CREBBPCNR1LMNA | |
| SCHEMBL18616173 | 0.76 | MCL1 (0.40) | CYP19A1MAPTCNR1PTPN7 | |
| SCHEMBL4685270 | 0.75 | NR4A2 (0.57) | CYP19A1CREBBPALDH1A1MAPTLMNA | |
| SCHEMBL14522478 | 0.75 | ICMT (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655359-B1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9364459-B2 | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2512469-B1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2513089-B1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9012659-B2 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-04-21 | — | — | US | disclosed |
| US-8957103-B2 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20130345281-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-12-26 | — | — | US | disclosed |
| EP-2655359-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2474541-A1 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes- Gutenberg-Universität Mainz (DE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012084683-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2343291-A1 | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338486-A1 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | SI, AADAC, INMT | CYP19A1 643/4885CREBBP 3376/4885ALDH1A1 94/4885 |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, INMT, IDH1 | CYP19A1 350/4885CREBBP 3320/4885ALDH1A1 116/4885 |
| US-20130345281-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, IDH1, INMT | CYP19A1 647/4885CREBBP 4344/4885ALDH1A1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.